Page last updated: 2024-09-05

sb 203580 and lfm a13

sb 203580 has been researched along with lfm a13 in 2 studies

Compound Research Comparison

Studies
(sb 203580)
Trials
(sb 203580)
Recent Studies (post-2010)
(sb 203580)
Studies
(lfm a13)
Trials
(lfm a13)
Recent Studies (post-2010) (lfm a13)
3,48941,13724010

Protein Interaction Comparison

ProteinTaxonomysb 203580 (IC50)lfm a13 (IC50)
Tyrosine-protein kinase BTK Mus musculus (house mouse)2.5
Tyrosine-protein kinase BTKHomo sapiens (human)2.5
Serine/threonine-protein kinase PLK3Homo sapiens (human)7.2

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (50.00)29.6817
2010's1 (50.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Bullock, AN; Fedorov, O; Knapp, S; Marsden, B; Müller, S; Pogacic, V; Rellos, P; Schwaller, J; Sundström, M1
Dart, ML; Hartnett, JR; Jost, E; Killoran, MP; Kirkland, TA; Machleidt, T; Robers, MB; Schwinn, MK; Shi, C; Wilkinson, JM; Wood, KV; Zimmerman, K1

Other Studies

2 other study(ies) available for sb 203580 and lfm a13

ArticleYear
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
    Proceedings of the National Academy of Sciences of the United States of America, 2007, Dec-18, Volume: 104, Issue:51

    Topics: Amino Acid Sequence; Binding Sites; Clinical Trials as Topic; Drug Evaluation, Preclinical; Enzyme Stability; Humans; Molecular Sequence Data; Phylogeny; Protein Array Analysis; Protein Conformation; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases

2007
Homogeneous Assay for Target Engagement Utilizing Bioluminescent Thermal Shift.
    ACS medicinal chemistry letters, 2018, Jun-14, Volume: 9, Issue:6

    Topics:

2018